Help me fill in the blanks of the practice of ED Critical Care. In this podcast, we discuss all things related to the crashing, critically ill patient in the Emergency Department. Find the show notes at emcrit.org.
…
continue reading
Indhold leveret af Dr Neil Love. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Dr Neil Love eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !
Gå offline med appen Player FM !
Myeloproliferative Neoplasms | Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from Recent Major Conferences
MP4•Episode hjem
Manage episode 414405004 series 2513286
Indhold leveret af Dr Neil Love. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Dr Neil Love eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Featuring perspectives from Dr Naveen Pemmaraju, including the following topics:
- Recent developments in management approaches for myelofibrosis prior to ASH 2023 (0:00)
- Updated data with navitoclax in combination with ruxolitinib for patients with myelofibrosis (12:35)
- Key findings with pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve myelofibrosis in the Phase III MANIFEST-2 study (22:21)
- Long-term follow-up from the Phase I/III XPORT-MF-034 trial of selinexor with ruxolitinib for JAK inhibitor-naïve myelofibrosis (29:10)
- Effect of new or worsening anemia on clinical outcomes in patients with myelofibrosis treated with ruxolitinib in the expanded-access JUMP study (34:33)
- Results from the Phase III FREEDOM-2 study of fedratinib for patients with myelofibrosis after prior ruxolitinib (40:38)
- Landmark survival analysis of the Phase III PERSIST-2 trial evaluating pacritinib versus best available therapy in patients with myelofibrosis and thrombocytopenia (43:08)
- Retrospective analysis of the PAC203 and PERSIST-2 studies of pacritinib for cytopenic myelofibrosis (47:56)
- Longitudinal assessment of transfusion intensity in patients who received momelotinib for myelofibrosis in the Phase III SIMPLIFY-1 and MOMENTUM trials (52:48)
- Two-year follow-up from the Phase II REVIVE study of rusfertide in phlebotomy-dependent patients with polycythemia vera (55:18)
- Available Phase I/II data with the novel agent zilurgisertib with or without ruxolitinib in patients with anemia due to myelofibrosis (58:56)
1291 episoder
MP4•Episode hjem
Manage episode 414405004 series 2513286
Indhold leveret af Dr Neil Love. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Dr Neil Love eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Featuring perspectives from Dr Naveen Pemmaraju, including the following topics:
- Recent developments in management approaches for myelofibrosis prior to ASH 2023 (0:00)
- Updated data with navitoclax in combination with ruxolitinib for patients with myelofibrosis (12:35)
- Key findings with pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve myelofibrosis in the Phase III MANIFEST-2 study (22:21)
- Long-term follow-up from the Phase I/III XPORT-MF-034 trial of selinexor with ruxolitinib for JAK inhibitor-naïve myelofibrosis (29:10)
- Effect of new or worsening anemia on clinical outcomes in patients with myelofibrosis treated with ruxolitinib in the expanded-access JUMP study (34:33)
- Results from the Phase III FREEDOM-2 study of fedratinib for patients with myelofibrosis after prior ruxolitinib (40:38)
- Landmark survival analysis of the Phase III PERSIST-2 trial evaluating pacritinib versus best available therapy in patients with myelofibrosis and thrombocytopenia (43:08)
- Retrospective analysis of the PAC203 and PERSIST-2 studies of pacritinib for cytopenic myelofibrosis (47:56)
- Longitudinal assessment of transfusion intensity in patients who received momelotinib for myelofibrosis in the Phase III SIMPLIFY-1 and MOMENTUM trials (52:48)
- Two-year follow-up from the Phase II REVIVE study of rusfertide in phlebotomy-dependent patients with polycythemia vera (55:18)
- Available Phase I/II data with the novel agent zilurgisertib with or without ruxolitinib in patients with anemia due to myelofibrosis (58:56)
1291 episoder
Alle episoder
×Velkommen til Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.